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DInnovation in both operative techniques and devices has
been a hallmark of thoracic surgery since its inception.
Included has been the search for the optimal prosthetic
patch, a quest that has been ongoing since the earliest years
of congenital heart repairs. A biologic scaffold that allows
recipient cellular ingrowth and remodeling with subsequent
appropriate native tissue function and growth potential
would be the ultimate solution to the patch dilemma.
When animal studies suggested that an extracellular matrix
made from the submucosa of porcine small intestine
(CorMatrix; CorMatrix Cardiovascular, Inc, Roswell, Ga)
provided a bioscaffold that allowed ingrowth of ‘‘organized
and healthy tissue,’’ optimism, perhaps out of proportion to
the evidence base, ensued. Written information provided by
the manufacturer1 further suggested that their acellular
biomaterial could be expected to regulate cell adhesion,
cell differentiation, cell division, and cell migration.
CorMatrix was initially recommended for pericardial
reconstruction and, again according to the company’s
brochure, ‘‘Clinical data suggest complete reformation of
the pericardial space, including an intact mesothelial
lining.’’ Interestingly, a recent publication, ‘‘Histology of
CorMatrix Bioscaffold 5 Years After Pericardial Closure,’’reported that with regard to the histologic analysis of the
explanted pericardial patch ‘‘no evidence was found of an
endothelial lining on the putative visceral face of the sam-
ple.’’2 This suggested that further investigation into the
behavior of CorMatrix, even when used in its most funda-
mental application, was warranted.
It seems fair to say that evidence showing that CorMatrix
remodels and restores function when used for cardiac valve
reconstruction is at best scanty and is based primarily on
animal studies (where in many cases the bioscaffold was
allogeneic) and clinical reports with relatively small
numbers of patients and short follow-up describing echo-
cardiographic findings of repaired valves.3 This reinforces
the importance of this article by Zaidi and colleagues4
from Boston Children’s Hospital, which gives us histologic
information on the status of cardiac valve patches explanted
after failed valve repairs.
The study has several weaknesses recognized by its
authors. The overall number of patients with CorMatrix
valve repairs was small, and the number of explants avail-
able for histologic study was even smaller (n ¼ 9). This
small sample was also divided between mitral (n ¼ 6) and
aortic (n¼ 3) reconstructions. The duration of implantation
was short in a number of patients, with only 5 of 9 patches in
situ longer than 3 months (101-261 days). The study thus
can’t address favorable remodeling that might be occurring
at a later point after implantation, because we have no data
on the status of the CorMatrix in patients with a more dura-
ble valve repair.
With that said, this is the largest experience with human
explants of CorMatrix used for valve repair, and the histo-
logic findings are consistent. There was an intense inflam-
matory response to the patches that did not abate as late
as 9 months. In some cases, this was associated with a
fibrous peel of neointima that appeared to be encasing the
CorMatrix. This mixed inflammatory infiltration is very
concerning and in keeping with histologic findings in previ-




Dlongest duration in situ was any significant resorption of the
bioscaffold seen. This is unexpected. Most disturbing was
the finding that there was little to no remodeling to form tis-
sue resembling a 3-layered native valve as late as 9 months
after implant. In fairness, there is no well-established evi-
dence base describing the expected time interval to remod-
eling, although animal data (of uncertain applicability)
would suggest an interval as short as 3 to 4 months.
So what are we to think? According to written materials
provided by the manufacturer, CorMatrix Cardiovascular,1
CorMatrix ECM Bioscaffold has Food and Drug Adminis-
tration clearance and a European CE Mark to be sold for
pericardial patch repair and reconstruction, cardiac tissue
repair, and carotid repair. They state, ‘‘It is an acellular
biomaterial that does not encapsulate when surgically
implanted, but is gradually remodeled, leaving behind orga-
nized healthy tissue.’’1 Is this really true? Onewonders what
evidence the Food and Drug Administration considered in
approving CorMatrix to be used for thewide range of poten-
tial applications that might be included under the descriptor
‘‘cardiac tissue repair.’’
This report by Zaidi and associates4 brings into ques-
tion a number of issues regarding the performance of2226 The Journal of Thoracic and Cardiovascular SurCorMatrix and reminds us that with innovation comes a
responsibility to examine and document outcomes care-
fully to be sure that what we are doing is at least as
good if not better for our patients than alternatives. It is
to be hoped that others who use CorMatrix will be as dili-
gent as the group at Boston Children’s and will document
their results when the opportunity arises. Innovation,
yes—as long as it is introspective, carefully studied, and
reasonably cautious.References
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